Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.54 |
| ▸ | ACP1 | P24666 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.50 |
| ▸ | PTPRF | P10586 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460257 | 0.94 | MEN1 (0.52) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5462867 | 0.83 | MEN1 (0.62) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5462864 | 0.83 | MEN1 (0.62) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5470519 | 0.79 | PTPN1 (0.54) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5470522 | 0.79 | PTPN1 (0.54) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5462464 | 0.78 | PTPN1 (0.59) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5462470 | 0.78 | PTPN1 (0.59) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5472001 | 0.77 | MEN1 (0.69) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5472003 | 0.77 | MEN1 (0.69) | PTPN1ACP1MEN1KMT2ANSD2 | |
| SCHEMBL5460256 | 0.76 | MEN1 (0.51) | PTPN1ACP1MEN1KMT2ANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | PTPN1 3264/4885ACP1 254/4885MEN1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.